Drug Patents owned by Heron Theraps Inc

1. List of Aponvie drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

2. List of Cinvanti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CINVANTI before it's patent expiration?
More Information on Dosage

3. List of Sustol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8715710 HERON THERAPS INC Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Sep, 2024

(1 year, 7 months from now)

US9913910 HERON THERAPS INC Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Sep, 2024

(1 year, 7 months from now)

US8252305 HERON THERAPS INC Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
Sep, 2024

(1 year, 7 months from now)

US10357570 HERON THERAPS INC Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Sep, 2024

(1 year, 7 months from now)

US8252304 HERON THERAPS INC Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Sep, 2024

(1 year, 7 months from now)

Drugs and Companies using GRANISETRON ingredient

Market Authorisation Date: 09 August, 2016

Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting

Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

4. List of Zynrelef Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592227 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US9744163 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US10398686 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US11253504 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US9913909 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US11413350 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US9694079 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US9801945 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10213510 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10098957 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10632199 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10898575 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US11083797 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US11083730 HERON THERAPS INC Long-acting polymeric delivery systems
Apr, 2035

(12 years from now)

US10980886 HERON THERAPS INC Compositions of a polyorthoester and an organic acid excipient
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 12, 2024

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation; Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in